ArticleEmerging infectious diseases2016
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis.Journal of managed care & specialty pharmacy · 2025Pooled it
- Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection.The Journal of infectious diseases · 2025Trial
- Article
- Article
- Efficacy and safety of Xiao'er Fengre Qing oral liquidFrontiers in pharmacology · 2025Article
- T-705-Derived Prodrugs Show High Antiviral Efficacies against a Broad Range of Influenza A Viruses with Synergistic Effects When Combined with Oseltamivir.Pharmaceutics · 2023Article
- Risk factors for in-hospital mortality and secondary bacterial pneumonia among hospitalized adult patients with community-acquired influenza: a large retrospective cohort study.Antimicrobial resistance and infection control · 2023Article
- Assessment of Temporal Patterns and Patient Factors Associated With Oseltamivir Administration in Children Hospitalized With Influenza, 2007-2020.JAMA network open · 2022Article
- Mechanism ofAnnals of translational medicine · 2022Article
- Protein Disulfide Isomerase A3 Regulates Influenza Neuraminidase Activity and Influenza Burden in the Lung.International journal of molecular sciences · 2022Article
- Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-Hôpitaux de Paris clinical data warehouse: a pilot study.Annals of intensive care · 2021Article
- Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract.Nature reviews. Microbiology · 2021Review
- Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations.GMS infectious diseases · 2021Review
- Covid-19 pandemic research opportunity: Is the Middle East & North Africa (MENA) missing out?Contemporary clinical trials · 2020Review
- Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.PLoS pathogens · 2020Article
- The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective.Frontiers in medicine · 2020Article
- An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells.Scientific reports · 2019Article
- Article
- Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?Viruses · 2018Article
- Oseltamivir Treatment of Influenza in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A debate about the market-leading influenza antiviral medication, oseltamivir, which initially focused on treatment for generally mild illness, has been expanded to question the wisdom of stockpiling for use in future influenza pandemics. Although randomized controlled trial evidence confirms that oseltamivir will reduce symptom duration by 17-25 hours among otherwise healthy adolescents and adults with community-managed disease, no randomized controlled trials have examined the effectiveness of oseltamivir against more serious outcomes. Observational studies, although criticized on methodologic grounds, suggest that oseltamivir given early can reduce the risk for death by half among persons hospitalized with confirmed infection caused by influenza A(H1N1)pdm09 and influenza A(H5N1) viruses. However, available randomized controlled trial data may not be able to capture the effect of oseltamivir use among hospitalized patients with severe disease. We assert that data on outpatients with relatively mild disease should not form the basis for policies on the management of more severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.